Company News

TenNor Completed 264 million RMB Series D Financing

2022-03-30
March 30, 2022 TenNor Therapeutics (Suzhou) Limited announced the completion of 264 million RMB series D financing, led jointly by Yanchuang Capital and GTJA Investment, followed by Galaxy Capital,...

TENNOR DISCLOSES OF TNP-2198 FOR H. PYLORI INFECTIONS

2022-02-18
TenNor Discloses TNP-2198 for the Treatment of H. pylori Infections in the Journal of Medicinal Chemistry February 18, 2022 TNP-2198, a stable conjugate of a rifamycin pharmacophore and a nitr...

TenNor Reports Positive Phase II Results for TNP-2092 Capsule

2021-11-23
SUZHOU, China, Nov. 22, 2021 --TenNor Therapeutics reports positive top-line results for TNP-2092 Capsule from a phase II clinical trial for the treatment of hyperammonemia/hepatic encephalopathy i...

TenNor's TNP-2092 and TNP-2198 Were Featured in WHO Report in 2020 Antimicrobial Agent Pipeline

2021-04-16
TenNor’s TNP-2092 and TNP-2198 Were Featured in WHO Report in 2020 Antimicrobial Agent PipelineLink to the article:Antib...

Drug of the Future Publish Review Article on TNP-2092

2021-02-20
Drugs Fut 2021, 46(2): 129ISSN 0377-8282Copyright 2021 Clarivate AnalyticsCCC: 0377-8282DOI: 10.1358/dof.2021.46.2.31768...

COLLABORATING FOR POTENTIAL NEW TREATMENTS FOR NTM DISEASES

2021-01-21
With rising Nontuberculous Mycobacteria (NTM) incidence rates and a lack of effective diagnostic tests, vaccines and imm...

TenNor Enters Research Collaboration with Janssen for Potential New Treatments for NTM Diseases

2021-01-18
SUZHOU, China, Jan. 18, 2021 -- TenNor Therapeutics (Suzhou) Limited, a clinical-stage biopharmaceutical company dedic...

ABC/ABCI and TenNor Therapeutics signed strategic partnership agreement

2020-10-25
Agriculture Bank of China (ABC) together with Agriculture Bank of China International (ABCI) signed agreement to form s...

TenNor Initiated TNP-2198 Phase 1b/IIa Clinical Trials

2020-10-12
October 12, 2020/Changchun -- The phase Ib/IIa site initiation meeting of TNP-2198 for the treatment of Helicobacter pyl...

TenNor presented Phase II results of TNP-2092 at 2020 CBIIC

2020-09-28
September 27, 2020/Suzhou --- TenNor Therapeutics presented Phase II results of TNP-2092 at 2020 China Biomed Innovation...

TenNor Initiated Phase II Clinical Trial for Cirrhosis Hyperammonemia and Hepatic Encephalopathy

2020-08-14
August 14, 2020. The phase II site initiation meeting of TNP-2092 capsule for the treatment of cirrhosis hyperammonemia ...

TenNor Was Named as One of the Potential Unicorn Enterprises in Suzhou

2020-06-19
TenNor was named as One of the Potential Unicorn Enterprises in Suzhou.Please click here for details:

TenNor Publishes Article on Synergistic Activity of Oxazolidinone-Nitroimidazole Conjugates

2020-05-25
The introductions of the bicyclic 4‐nitroimidazole and the oxazolidinone classes of antimicrobial agents represented the...

In vitro activity of TNP-2092 against periprosthetic joint infection–associated staphylococci

2020-03-20
Please read the article through this link: https://www.sciencedirect.com/science/article/abs/pii/S0732889319307229

BioWorld Reports Recent Progress of TenNor Therapeutics

2020-01-30
Please read the details through this link: https://www.bioworld.com/articles/432589-tennors-prosthetic-joint-infections-...

TenNor Therapeutics Received FDA Orphan Drug Designation

2020-01-20
SUZHOU, China, Jan. 20, 2020 /PRNewswire/ -- TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has...

TenNor publishes article on TNP-2092 PO Potential Application in the Treatment of Gastrointestinal

2019-12-20
TenNor publishes article on TNP-2092 PO Potential Application in the Treatment of Gastrointestinal and Liver Disorders i...

TenNor Therapeutics Released Phase II Top-Line Results for TNP-2092

2019-11-13
November 11, 2019/Suzhou/China – TenNor Therapeutics released positive top-line results for TNP-2092 powder for injectio...

TenNor Receives QIDP Designation for TNP-2092

2019-02-17
February 27, 2019/Suzhou/ -- TenNor Therapeutics Limited, a clinical-stage company focused on developing differentiated ...

TNP2198,TenNor's new drug for anaerobic bacterial infections,has been approved for clinical research

2018-12-03
TenNor’s class I new drug, TNP-2198 capsule, has been approved by CDE for the initiation of clinical studies. This is Te...

TenNor starts phase II clinical trial in USA with the novel antibiotic candidate TNP-2092

2018-08-02
TenNor held a kick-off meeting for the phase II clinical trial of TNP-2092 IV in San Francisco on Aug. 2, 2018. This pro...

TenNor Presented at 9th China Healthcare Investment Conference

2018-04-04
The 9th China Healthcare Investment Conference (CHIC) was held on March 28-29, 2018 in Shanghai. Dr. Zhenkun Ma, Founder...

Held Its First Clinical Advisory Meeting on TNP-2092 for the Treatment of Prosthetic Joint Infection

2017-05-10
TenNor Therapeutics held its first Clinical Advisory Meeting on TNP-2092 for the treatment of prosthetic joint infection...

TenNor Therapeutics Announces $25 Million Series B Financing to Advance TNP-2092 Clinical Trials

2016-09-19
TenNor Therapeutics today announced a $25 million Series B financing led by Northern Light Venture Capital. Joining this...

TenNor’s Publication on TNP-2092 was Selected as ACS Editors’ Choice

2016-08-11
TenNor’s article “Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial ...

TenNor Releases TNP-2092 Information during ASM Microbe 2016 Conference

2016-06-27
TenNor Therapeutics team attended ASM Microbe 2016 Conference held in Boston USA and presented TNP-2092 for Helicobacter...

Received Government Grant to Support Development of Dua-Action Molecules for the Treatment of MDR

2016-02-02
TenNor Therapeutics Received Government Grant to Support Development of Dua-Action Molecules for the Treatment of MDR/XD...

TenNor Participates and Presents in the 10th Chinese H. pylori and Digestive Diseases Forum

2015-08-31
The 10th Chinese H. pylori and Digestive Diseases Forum was held in Beijing on August 21-23, 2015. Established in 2006, ...

NIH Guests Visited TenNor Therapeutics

2015-06-08
Dr. Dennis M. Dixon, Chief, Bacteriology and Mycology Branch, Dr. Lanling Zou, Chief of Translational Sciences and Dr. P...

TenNor Therapeutics Attended The 9th Chinese H. pylori and Digestive Diseases Forum

2014-08-12
Attended by specialists in the digestive disease area, the 9th Chinese H. pylori and Digestive Diseases Forum was held i...

TenNor Held First Scientific Advisory Board Meeting

2014-06-20
TenNor Therapeutics held its first Scientific Advisory Board (SAB) Meeting on June 13, 2014 in Suzhou. SAB members inclu...

TenNor was invited to speak at 5th China Healthcare Investment Conference

2014-04-06
The 5th China Healthcare Investment Conference (CHIC) was held on March 4-6, 2014 in Shanghai. Dr. Zhenkun Ma, Founder a...

TenNor Acquires Patent from TB Alliance

2014-03-12
NEW YORK, NY – TB Alliance, an international non-profit drug development organization that develops better, faster-actin...

TenNor Therapeutics Develop Dual-Action Molecules

2013-11-19
Finding a way out of the dilemma of drug resistanceHelicobacter pylori (Hp) is the main cause of chronic gastritis, gast...
©2013 丹诺医药(苏州)有限公司 版权所有 苏ICP备14011456号-1 | 管理登录
©2013 丹诺医药(苏州)有限公司 版权所有 苏ICP备14011456号-1 | 管理登录
©2013 TENNOR THERAPEUTICS LTD